{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T04:15:51Z","timestamp":1789532151301,"version":"build-2803163510"},"reference-count":22,"publisher":"The Endocrine Society","issue":"7","license":[{"start":{"date-parts":[[2024,7,24]],"date-time":"2024-07-24T00:00:00Z","timestamp":1721779200000},"content-version":"vor","delay-in-days":27,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,6,27]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>A 71-year-old woman was diagnosed with unresectable metastatic follicular thyroid carcinoma (FTC) and thyrotoxicosis. She was negative for the presence of thyroxine receptor antibody and thyroid-stimulating antibody. Whole-body scintigraphy revealed increased 99mTc-pertechnetate uptake in metastatic bone lesions but not in the thyroid nodule. Since radioactive iodine therapy was not applicable because the canalis vertebralis had been invaded, treatment with lenvatinib was initiated, along with methimazole and potassium iodide. The serum level of thyroid hormone decreased. The patient developed hypothyroidism, which continued after the methimazole was stopped, suggesting that lenvatinib suppressed the hyperthyroidism. To our best knowledge, this is the first report of a patient with functioning bone lesions of metastatic FTC in whom hyperthyroidism was controlled by lenvatinib without radioactive iodine therapy.<\/jats:p>","DOI":"10.1210\/jcemcr\/luae139","type":"journal-article","created":{"date-parts":[[2024,7,25]],"date-time":"2024-07-25T02:20:56Z","timestamp":1721874056000},"source":"Crossref","is-referenced-by-count":1,"title":["Hyperthyroidism Due to Functioning Metastatic Bone Lesions of Follicular Thyroid Carcinoma Treated With Lenvatinib"],"prefix":"10.1210","volume":"2","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3151-1287","authenticated-orcid":false,"given":"Tomoko","family":"Kobayashi","sequence":"first","affiliation":[{"name":"Department of Endocrinology and Diabetes, Nagoya University Graduate School of Medicine , Nagoya 466-8550 , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shintaro","family":"Iwama","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Diabetes, Nagoya University Graduate School of Medicine , Nagoya 466-8550 , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Suzuki","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Diabetes, Nagoya University Graduate School of Medicine , Nagoya 466-8550 , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Arima","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Diabetes, Nagoya University Graduate School of Medicine , Nagoya 466-8550 , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2024,7,24]]},"reference":[{"issue":"7","key":"2024072615162094100_luae139-B1","first-page":"1202","article-title":"Severe thyrotoxicosis due to functioning pulmonary metastases of well-differentiated thyroid cancer","volume":"39","author":"Salvatori","year":"1998","journal-title":"J Nucl Med"},{"issue":"950","key":"2024072615162094100_luae139-B2","doi-asserted-by":"crossref","first-page":"e38","DOI":"10.1259\/bjr\/52032397","article-title":"Differentiated thyroid cancer presenting with thyrotoxicosis due to functioning metastases","volume":"80","author":"Haq","year":"2007","journal-title":"Br J Radiol"},{"issue":"4","key":"2024072615162094100_luae139-B3","doi-asserted-by":"crossref","first-page":"108","DOI":"10.3390\/cancers10040108","article-title":"Immunohistochemistry for diagnosis of metastatic carcinomas of unknown primary site","volume":"10","author":"Selves","year":"2018","journal-title":"Cancers (Basel)"},{"issue":"8","key":"2024072615162094100_luae139-B4","doi-asserted-by":"crossref","first-page":"E1074","DOI":"10.1210\/jc.2015-1967","article-title":"Thyroglobulin (Tg) testing revisited: Tg assays, TgAb assays, and correlation of results with clinical outcomes","volume":"100","author":"Netzel","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"2024072615162094100_luae139-B5","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1507\/endocrj.EJ20-0025","article-title":"The revised clinical practice guidelines on the management of thyroid tumors by the Japan Associations of Endocrine Surgeons: core questions and recommendations for treatments of thyroid cancer","volume":"67","author":"Ito","year":"2020","journal-title":"Endocr J"},{"issue":"1","key":"2024072615162094100_luae139-B6","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1677\/erc.1.00830","article-title":"rhTSH-aided radioiodine ablation and treatment of differentiated thyroid carcinoma: a comprehensive review","volume":"12","author":"Luster","year":"2005","journal-title":"Endocr Relat Cancer"},{"issue":"9","key":"2024072615162094100_luae139-B7","doi-asserted-by":"crossref","first-page":"4122","DOI":"10.1210\/jc.2001-011147","article-title":"Survival analysis of 19 patients with toxic thyroid carcinoma","volume":"87","author":"Als","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2024072615162094100_luae139-B8","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1002\/jso.20508","article-title":"The incidence of hyperthyroidism in patients with thyroid cancer in an area of iodine deficiency","volume":"94","author":"Gulcelik","year":"2006","journal-title":"J Surg Oncol"},{"issue":"11","key":"2024072615162094100_luae139-B9","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1089\/thy.2000.10.1009","article-title":"A Phe 486 thyrotropin receptor mutation in an autonomously functioning follicular carcinoma that was causing hyperthyroidism","volume":"10","author":"Camacho","year":"2000","journal-title":"Thyroid"},{"issue":"3","key":"2024072615162094100_luae139-B10","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1530\/ERC-11-0306","article-title":"Thyroid-specific ablation of the Carney complex gene, PRKAR1A, results in hyperthyroidism and follicular thyroid cancer","volume":"19","author":"Pringle","year":"2012","journal-title":"Endocr Relat Cancer"},{"issue":"6","key":"2024072615162094100_luae139-B11","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1507\/endocrj.44.855","article-title":"Appearance of TSH receptor antibody and hyperthyroidism associated with metastatic thyroid cancer after total thyroidectomy","volume":"44","author":"Yoshimura Noh","year":"1997","journal-title":"Endocr J"},{"issue":"6","key":"2024072615162094100_luae139-B12","first-page":"535","article-title":"Hyperfunctioning thyroid carcinoma: a systematic review","volume":"11","author":"Liu","year":"2019","journal-title":"Mol Clin Oncol"},{"issue":"5","key":"2024072615162094100_luae139-B13","doi-asserted-by":"crossref","first-page":"458","DOI":"10.4158\/EP08300.CRR","article-title":"Unusual initial manifestation of metastatic follicular carcinoma of the thyroid with thyrotoxicosis diagnosed by technetium Tc 99m pertechnetate scan: case report and review of literature","volume":"15","author":"Sundaraiya","year":"2009","journal-title":"Endocr Pract"},{"issue":"1","key":"2024072615162094100_luae139-B14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1089\/thy.2015.0020","article-title":"2015 American Thyroid Association Management Guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association Guidelines Task Force on thyroid nodules and differentiated thyroid cancer","volume":"26","author":"Haugen","year":"2016","journal-title":"Thyroid"},{"issue":"7","key":"2024072615162094100_luae139-B15","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1056\/NEJMoa1406470","article-title":"Lenvatinib versus placebo in radioiodine-refractory thyroid cancer","volume":"372","author":"Schlumberger","year":"2015","journal-title":"N Engl J Med"},{"issue":"10126","key":"2024072615162094100_luae139-B16","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","article-title":"Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial","volume":"391","author":"Kudo","year":"2018","journal-title":"Lancet"},{"issue":"1","key":"2024072615162094100_luae139-B17","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s00535-019-01642-1","article-title":"REFLECT-a phase 3 trial comparing efficacy and safety of lenvatinib to sorafenib for the treatment of unresectable hepatocellular carcinoma: an analysis of Japanese subset","volume":"55","author":"Yamashita","year":"2020","journal-title":"J Gastroenterol"},{"issue":"9","key":"2024072615162094100_luae139-B18","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1507\/endocrj.EJ19-0140","article-title":"Lenvatinib-induced thyroid abnormalities in unresectable hepatocellular carcinoma","volume":"66","author":"Koizumi","year":"2019","journal-title":"Endocr J"},{"issue":"11","key":"2024072615162094100_luae139-B19","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1089\/thy.2015.0170","article-title":"Thyroid dysfunction in patients with metastatic carcinoma treated with sunitinib: is thyroid autoimmunity involved?","volume":"25","author":"Pani","year":"2015","journal-title":"Thyroid"},{"key":"2024072615162094100_luae139-B20","doi-asserted-by":"crossref","first-page":"978","DOI":"10.3389\/fimmu.2018.00978","article-title":"Targeting VEGF\/VEGFR to modulate antitumor immunity","volume":"9","author":"Yang","year":"2018","journal-title":"Front Immunol"},{"issue":"9","key":"2024072615162094100_luae139-B21","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1038\/nrendo.2014.114","article-title":"VEGF-targeted cancer therapeutics-paradoxical effects in endocrine organs","volume":"10","author":"Cao","year":"2014","journal-title":"Nat Rev Endocrinol"},{"issue":"3","key":"2024072615162094100_luae139-B22","doi-asserted-by":"crossref","first-page":"380","DOI":"10.2478\/raon-2023-0034","article-title":"Treatment and outcome of patients with Graves\u2019 disease and metastatic differentiated thyroid cancer","volume":"57","author":"Besic","year":"2023","journal-title":"Radiol Oncol"}],"container-title":["JCEM Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcemcr\/article-pdf\/2\/7\/luae139\/58660148\/luae139.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcemcr\/article-pdf\/2\/7\/luae139\/58660148\/luae139.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,27]],"date-time":"2024-07-27T00:56:34Z","timestamp":1722041794000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcemcr\/article\/doi\/10.1210\/jcemcr\/luae139\/7718918"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,27]]},"references-count":22,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,6,27]]}},"URL":"https:\/\/doi.org\/10.1210\/jcemcr\/luae139","relation":{},"ISSN":["2755-1520"],"issn-type":[{"value":"2755-1520","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,7]]},"published":{"date-parts":[[2024,6,27]]},"article-number":"luae139"}}